Renuka Iyer, MD

Associate Professor of Oncology

Co-Director, Liver and Pancreas Tumor Program

Section Chief for Gastrointestinal Oncology

Roswell Park Cancer Institute

Assistant Professor of Medicine

School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise:

Bile duct cancer

Carcinoid

Cholangiocarcinoma

Esophageal cancer

Hepatocellular cancer

Pancreatic cancer

Research

Research Interests:

Developing novel treatments for patients with hepatocellular, pancreaticobiliary and neuroendocrine cancers

Studies of novel targeted therapies in a woodchuck model of liver cancer

Understanding the mechanism of the anticancer effects of vitamin D

Background Information

Education and Training:

Grant Medical College, University of Mumbai, Maharashtra, India

Residency:

Lincoln Medical and Mental Health Center, Cornell University, New York, NY

Board Certification:

Internal Medicine, American Board of Internal Medicine

Medical Oncology, American Board of Internal Medicine

Fellowships:

Roswell Park Cancer Institute, Buffalo, NY

Publications

Publications:

Iyer R, Bharthuar A. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert opinion on pharmacotherapy 2010; 11(2):311-320
May KS, Javle MM, Gibbs JF, Kuvshinoff BW, Fakih M, Russo RC, Flaherty L, Ma WW, Iyer RV, Wilding GE, Chandrasekhar R, Khushalani NI, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. International journal of radiation oncology, biology, physics 2010; 76(4):1193-1198
Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert opinion on pharmacotherapy 2010; 11(11):1943-1955
Mahajan P, Weber-Shrikant E, Iyer R, Sitrin M, Lohr J, Arora P. CKD in a patient with pancreatic carcinoma. American journal of kidney diseases 2010; 56(3):591-594
Yang GY, Fakih M, Gibbs JF, Yendamuri SS, Khushalani NI, McCloskey SA, Wilding GE, Chandrasekhar R, Iyer RV, May KS, Thomas Jr CR. Renal atrophy secondary to chemoradiotherapy of abdominal malignancies. International journal of radiation oncology, biology, physics 2010; 78(2):539-546
Yu J, Kepner JL, Iyer R. "Exact permutation tests for correlated binomial variables" reply. Biometrical journal 2010; 52(3):438-439
Patel AV, Khorana AA, Bharthuar A, Kuvshinoff BW, Mackman N, Hutson A, Iyer RV. Tissue factor is associated with a prothrombotic state in pancreaticobiliary cancer (PBC). Annals of surgical oncology 2010; 17(Suppl. 1):S96
Malik NK , Wilding GE , Gibbs JF , Kuvshinoff BW , Iyer RV , Flaherty L , Ma W , May KS , Chandrasekhar R , Yang GY. Chemoradiotherapy vs. chemotherapy alone in patients with locally advanced unresectable pancreatic carcinoma: a 10-year experience. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S311-S312
May KS , Lamonica D , Nava HR , Gibbs JF , Yendamuri SS , Nwogu CE , Iyer RV , Yap JC , Warner JC , Russo RC , Malhotra HK , Flaherty L , Wilding GE , Chandrasekhar R , Khushalani NI , Yang GY , Thomas Jr CR. Association of Technetium(99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies. Journal of gastrointestinal oncology 2010; 1(1):7-15
Buitrago S, Curtin LI, Bellezza CA, Tennant BC, Iyer R. Repeated dynamic contrast enhanced magnetic resonance imaging using a vascular access port in the woodchuck (Marmota monax). Journal of the American Association for Laboratory Animal Science : JAALAS 2010; 49(5):694
Iyer RV, Johnson CS, Ramnath N, Fakih M, Muindi J, Wilding GE, Tan W, Javle MM, Fetterly GJ, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. Journal of clinical oncology 2010; 28(15 Suppl.):e13031
Khushalani NI, Fetterly GJ, Iyer RV, Litwin A, Brady W, Javle MM. Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. Journal of clinical oncology 2010; 28(15 Suppl.):TPS201
Khushalani NI, Nava HR, Nwogu CE, Yendamuri SS, Iyer RV, Wang D, Miecznikowski J, Tan W, Yang G, Javle MM. Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). Journal of clinical oncology 2010; 28(15 Suppl.):4100
Bharthuar A, Khorana AA, Mackman N, Hutson A, Patel A, Iyer RV. Association of tissue factor with prothrombotic state in pancreaticobiliary cancer (PBC) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #158
Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, Iyer RV. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer chemotherapy and pharmacology 2009; 64(1):177-181
Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas 2009; 10(5):523-527
Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP : Journal of the pancreas 2009; 10(5):535-538
Chadha MK, Javle MM, Kuvshinoff B, Gibbs JF, Raczyk C, Litwin A, Wilding GE, Mashtare T, Lombardo J, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer research 2009; 29(10):4127-4130
Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British journal of cancer 2009; 100(12):1842-1845
Yu J, Kepner JL, Iyer R. Exact tests using two correlated binomial variables in contemporary cancer clinical trials. Biometrical journal 2009; 51(6):899-914
Iyer R, Javle M, Robins M, Levea C, Litwin A, Nava H, Tan W, Shefter T, Yang G, Khushalani NI. Phase II multicenter study of erlotinib and radiation therapy (RT) for elderly patients (PTS) with esophageal carcinoma (EC)- final report. Annals of oncology 2010; 21(Suppl. 8):259-260
Khushalani NI, Brady W, Fetterly G, Prey J, Levea C, Litwin A, Grande C, Iyer R, Javle M. Continuous and intermittent vorinostat (V) in combination with folfiri in advanced upper gastrointestinal cancer (AUGC): Preliminary results of a phase I pharmacokinetic (PK) study. Annals of oncology 2010; 21(Suppl. 8):260
Thatikonda C, Miller A, Iyer R. Meta analysis of oxaliplatin-based combination chemotherapy for advanced gallbladder and bile duct cancers (AGBC). American journal of gastroenterology 2010; 105(Suppl. 1):194
Iyer R, Egloff L, Fraas J, Harris JD. Urinary and rectal incontinence during gabapentin therapy. Journal of supportive oncology 2008; 6(4):152
Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. American journal of clinical oncology 2008; 31(4):329-334
Ramnath N, Yu J, Khushalani NI, Gottlieb RH, Schwarz JK, Iyer RV, Rustum YM, Creaven PJ. Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anti-cancer drugs 2008; 19(7):749-752
Chadha MK, Iyer R, Nava ME, Abdelhalim A, Gibbs JF. Leptomeningeal metastases from signet ring adenocarcinoma of the cecum. Journal of clinical oncology 2007; 25(31):5028-5029
Foster JM, Hoshi H, Gibbs JF, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Annals of surgical oncology 2007; 14(2):833-840
Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Annals of surgical oncology 2007; 14(11):3202-3209
Javle M, Shah P, Yu J, Bhagat V, Litwin A, Iyer R, Gibbs J. Cystic pancreatic tumors (CPT): predictors of malignant behavior. Journal of surgical oncology 2007; 95(3):221-228
Javle MM, Iyer RV, Noel DC, Creaven PJ, Smith PF, Lawrence DD, Pendyala L, Durrani FA, Cao S, Rustum YM. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clinical cancer research 2007; 13(3):965-971
Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 2007; 73(5-6):281-289
Vinjamaram S, Iyer R. Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin. Cancer chemotherapy and pharmacology 2011; 68(1):225-226
Iyer RV, Yang G, Schefter TE, Tan W, Nava HR, Levea C, Litwin A, Robins M, Khushalani NI. Phase II multicenter study of erlotinib with radiation therapy (RT) for elderly patients (pts) with esophageal carcinoma (EC): Final report : 2011 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2011; 29(4 Suppl.):135
Bharthuar A, Khoury T, Haas KN, Mashtare T, Black J, Baer M, Yang G, Khushalani N, Iyer RV. Expression of breast cancer resistance protein (BCRP) in esophageal cancers (EC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e13529
Chadha K, Mashtare T, Iyer R. Clinical Outcomes in Metastatic Gastroenteropancreatic Neuro-endocrine Tumors (NETs) with Temozolomide and Thalidomide Combination Therapy. American journal of gastroenterology 2009; 104(Suppl. 3):Abstract #1102
Chadha M, Chadha K, Lombardo J, Mashtare T, Wilding G, Gibbs J, Kuvshinoff B, Litwin A, Raczyk C, Javle M, Iyer R. Dose Escalation of Octreotide Acetate for Management of Gastro-entero-pancreatic Neuroendocrine Tumors. American journal of gastroenterology 2009; 104(Suppl. 3):S103 (Abstract #268)
Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15540
Iyer R, Khushalani N, Tan W, Litwin A, LeVea C, Hutson A, Tucker C, Ma W, Fakih M, Adjei A. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). European journal of cancer (Oxford, England : 1990) 2009; 7(2):391
Iyer R, Rossi M, Javle M, Lo K, Cowell J, Khushalani N, Kuvshinoff B, Gibbs J. Evaluation of phosphatidyl inositol 3-kinase catalytic subunit (PI3KCA) and epidermal growth factor receptor (EGFR) gene mutations in pancreatic adenocarcinoma. Annals of surgical oncology 2008; 15(Suppl. 2):33
Iyer R, Tennant B, Brekken R, Rivera L, Pendyala L, Wu J, Fetterly G, Johnson C, Trump D. Woodchuck hepatocellular cancer (HCC): a translational model for developing anti-angiogenic therapies for human hepatocellular cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:690
Javle M, Yu J, Pande A, Garrett C, Kuvshinoff B, Litwin A, Gibbs J, Iyer R. Bevacizumab in combination with gemcitabine and capecitabine improves quality of life in patients with advanced pancreatic cancer (APC) - final results of the multicenter phase II study. Annals of oncology 2008; 19(Suppl. 6):67
Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L. Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15543
May KS, Fakih M, Khushalani N, Chandrasekhar R, Wilding G, Park L, Flaherty L, Russo R, Iyer R, Yang G. Renal Function following Abdominal Chemoradiotherapy for Gastrointestinal Malignancies in Elderly Patients. International journal of radiation oncology, biology, physics 2009; 75(3 Suppl.):S268-S269
May KSS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M. Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15532
Sharma R, Yang GY, Nava HR, Demmy TL, Nwogu CE, Yendamuri SS, Lamonica D, Tan W, Iyer RV, Khushalani NI. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15619
Shukla S, Iyer R. Vitamin D Levels and Neuroendocrine Tumors, Is There an Association: A Case Series. American journal of gastroenterology 2009; 104(Suppl. 3):Abstract #302
Vinjamaram S, Gibbs J, Khoury T, Repasky E, Hylander B, Iyer R. In vivo translational drug development model in pancreatic cancer. American journal of gastroenterology 2008; 103(Suppl. 1):S84 (Abstract #218)
Vinjamaram S, Khubchandani S, Iyer R. Sandostatin desensitization: a strategy useful for patients with carcinoid tumors, intolerant to sandostatin. American journal of gastroenterology 2008; 103(Suppl. 1):S358 (Abstract #912)
Yang GY, Flaherty L, Wagner TD, Yap JC, Chandrasekhar R, Wilding G, Khushalani NI, Iyer RV, Lamonica D, Thomas CR. Subclinical impairment of renal function following abdominal radiotherapy: An analysis using specific scintigraphic and biochemical endpoints. International journal of radiation oncology, biology, physics 2008; 72(1 Suppl.):S478-S479
Curtin LI, Buitrago S, Tennant B, Iyer R. Efficient Endpoint Monitoring of Hepatitis Virus-Infected Hepatocellular Carcinoma-Positive Woodchucks (Marmota monax) Using a Handheld Glucometer. Journal of the American Association for Laboratory Animal Science : JAALAS 2011; 50(5):734
Iyer R, Fetterly G, Groman A, Hutson A, Khushalani N, Mohile S, Ashton E, Litwin A, Grande C, Tomaszewski G. Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial. European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S447
Malik NK, May KS, Groman A, Patil S, Gibbs J, Kuvshinoff B, Ma W, Iyer R, Warren G, Yang G. Outcomes and Tolerability of Treatment for Locally Advanced Pancreatic Cancer Patients 65 Years or Older. International journal of radiation oncology, biology, physics 2011; 81(2 Suppl.):S336
Abbas A, Hutson A, Khorana A, Iyer R. Vitamin D's Role in Pathogenesis of Thromboembolism. Is This an Epiphenomenon?. American journal of gastroenterology 2011; 106(Suppl. 2):S55-S56
Ettinger DS, Agulnik M, Cates JMM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WN. NCCN Clinical Practice Guidelines in Oncology. Occult primary. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(12):1358-1395
Iyer R, Reddy K. The changing paradigm of treating pancreatic neuroendocrine tumors. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(12):1331-1333
Huang H, Salavaggione OE, Tennant B, Iyer RV, Adjei AA. Biochemical characterization of recombinant woodchuck vascular endothelium growth factor (wVEGF). Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5156
Benson AB, Strosberg JR, Fisher G, Malin JL, Anthony L, Arslan B, Gibbs JF, Greeno E, Iyer R, Kim MK, Maples W, Philip PA, Wolin E, Cherepanov D, Broder M. An Expert Panel Consensus on Medical Treatment of Non-Midgut Unresectable Neuroendocrine Tumors. Value in health 2012; 15(4):A229
Strosberg JR, Fisher G, Benson AB, Malin JL, Anthony L, Arslan B, Gibbs JF, Greeno E, Iyer R, Kim MK, Maples W, Philip PA, Wolin E, Cherepanov D, Broder M. Using the Modified RAND/UCLA Delphi Process to Produce Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors. Value in health 2012; 15(4):A228-A229
Ait-Oudhia S, Mager DE, Tomaszewski G, Groman AE, Zagst PD, Fetterly GJ, Iyer RV. Bridging sunitinib exposure to time-to-tumor progression in hepatocellular carcinoma patients with mathematical modeling of an angiogenic biomarker. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14690
Kotowski AS, Yarlagadda N, Salerno MK, Warren GW, Kuvshinoff BW, Wilkinson NW, Tan W, Iyer RV, Ma WW. Single institution experience of chemoradiation with gemcitabine versus capecitabine in borderline resectable and locally advanced pancreatic cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14659
Van Loon K, Kim GP, Espinoza AM, Fogelman DR, Iyer RV, Picozzi VJ, Wolff RA, Javle MM, Ko AH. A pooled analysis of phase II trials of gemcitabine (GEM)-containing doublets plus bevacizumab (BEV): Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer (APC)?. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4038
Al Ustwani O, Iancu D, Yacoub R, Iyer R. Detection of circulating tumor cells in cancers of biliary origin. Journal of gastrointestinal oncology 2012; 3(2):97-104
Iyer RV, Tomaszewski G, Wu YV, Kuvshinoff BW, Groman AE, Khushalani NI, Grande C, Zagst PD, Clark K, Fetterly GJ. Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #275
Reddy K, Ashton E, Buitrago S, Hutson A, Tennant BC, Iyer RV. Validating the woodchuck model for studying antiangiogenic therapies for human hepatocellular carcinoma (HCC) : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #239
Strosberg JR, Fisher GA, Benson AB, Malin JL, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Wolin EM, Cherepanov D, Broder MS. Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14610
Wu YV, Tomaszewski G, Groman AE, Iyer RV, Kuvshinoff BW. Yttrium-90 microspheres (SIR) verses transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS) : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #300

Referral

Email:

Renuka.Iyer@RoswellPark.org

Fax:

716-845-8935